374 related articles for article (PubMed ID: 20138655)
1. Utility of urine cytology in the workup of asymptomatic microscopic hematuria in low-risk patients.
Feifer AH; Steinberg J; Tanguay S; Aprikian AG; Brimo F; Kassouf W
Urology; 2010 Jun; 75(6):1278-82. PubMed ID: 20138655
[TBL] [Abstract][Full Text] [Related]
2. Editorial comment.
Lotan Y
Urology; 2010 Jun; 75(6):1282; author reply 1282-3. PubMed ID: 20513488
[No Abstract] [Full Text] [Related]
3. Evaluation of diagnostic strategies for bladder cancer using computed tomography (CT) urography, flexible cystoscopy and voided urine cytology: results for 778 patients from a hospital haematuria clinic.
Blick CG; Nazir SA; Mallett S; Turney BW; Onwu NN; Roberts IS; Crew JP; Cowan NC
BJU Int; 2012 Jul; 110(1):84-94. PubMed ID: 22122739
[TBL] [Abstract][Full Text] [Related]
4. Diagnostic tests in urology: urine cytology.
Lavallée LT; Fergusson D; Dahm P; Scales CD; Witiuk K; Breau RH
BJU Int; 2012 Dec; 110(11 Pt C):E789-91. PubMed ID: 23106855
[TBL] [Abstract][Full Text] [Related]
5. [The value of urine sediment cytomorphology in the ambulatory differential diagnosis of hematuria].
Obroniecka I; Rojewska J; Wańkowicz Z
Pol Merkur Lekarski; 1998 Nov; 5(29):285-7. PubMed ID: 10101502
[TBL] [Abstract][Full Text] [Related]
6. Use of a multitarget fluorescence in situ hybridization assay to diagnose bladder cancer in patients with hematuria.
Sarosdy MF; Kahn PR; Ziffer MD; Love WR; Barkin J; Abara EO; Jansz K; Bridge JA; Johansson SL; Persons DL; Gibson JS
J Urol; 2006 Jul; 176(1):44-7. PubMed ID: 16753364
[TBL] [Abstract][Full Text] [Related]
7. Fluorescence in situ hybridization assay detects upper urinary tract transitional cell carcinoma in patients with asymptomatic hematuria and negative urine cytology.
Huang WT; Li LY; Pang J; Ruan XX; Sun QP; Yang WJ; Gao X
Neoplasma; 2012; 59(4):355-60. PubMed ID: 22489689
[TBL] [Abstract][Full Text] [Related]
8. [Evaluation of urinary NMP22 (nuclear matrix protein 22) as a diagnostic marker for urothelial cancer--screening for urothelial cancer in patients with microscopic hematuria. NMP Study Group].
Akaza H; Miyanaga N; Tsukamoto T; Ishikawa S; Noguchi R; Ohtani M; Kawabe K; Kubota Y; Fujita K; Obata K; Hirao Y; Kotake T; Ohmori H; Kumazawa J; Koiso K
Gan To Kagaku Ryoho; 1997 May; 24(7):837-42. PubMed ID: 9170522
[TBL] [Abstract][Full Text] [Related]
9. Reflex ImmunoCyt testing for the diagnosis of bladder cancer in patients with atypical urine cytology.
Odisho AY; Berry AB; Ahmad AE; Cooperberg MR; Carroll PR; Konety BR
Eur Urol; 2013 May; 63(5):936-40. PubMed ID: 22521093
[TBL] [Abstract][Full Text] [Related]
10. NMP22: a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Potts JM; Kursh E; Novick A; Agarwal A
Anticancer Res; 1999; 19(4A):2621-3. PubMed ID: 10470205
[TBL] [Abstract][Full Text] [Related]
11. Editorial comment.
Jones JS
Urology; 2010 Jun; 75(6):1283; author reply 1283-4. PubMed ID: 20513490
[No Abstract] [Full Text] [Related]
12. Immunocyt test improves the diagnostic accuracy of urinary cytology: results of a French multicenter study.
Pfister C; Chautard D; Devonec M; Perrin P; Chopin D; Rischmann P; Bouchot O; Beurton D; Coulange C; Rambeaud JJ
J Urol; 2003 Mar; 169(3):921-4. PubMed ID: 12576813
[TBL] [Abstract][Full Text] [Related]
13. [Influence of blood cells in urine samples on results of screening for urothelial carcinoma with NMP22 bladder chek].
Ueda Y; Kawaguchi R; Takiuchi H; Kokura K; Yoshimoto T; Mitsui Y; Suzuki T; Jun Q; Higuchi Y; Maruyama T; Kondoh N; Nozima M; Yamamoto S; Shima H
Hinyokika Kiyo; 2009 Feb; 55(2):71-4. PubMed ID: 19301610
[TBL] [Abstract][Full Text] [Related]
14. [Can the combination of bladder ultrasonography and urinary cytodiagnosis replace cystoscopy in the diagnosis and follow-up of tumors of the bladder?].
Cariou G; Maaraoui N; Cortesse A
Prog Urol; 1997 Feb; 7(1):51-5. PubMed ID: 9116739
[TBL] [Abstract][Full Text] [Related]
15. Comparative predictive values of urinary cytology, urinary bladder cancer antigen, CYFRA 21-1 and NMP22 for evaluating symptomatic patients at risk for bladder cancer.
Sánchez-Carbayo M; Urrutia M; Silva JM; Romaní R; De Buitrago JM; Navajo JA
J Urol; 2001 May; 165(5):1462-7. PubMed ID: 11342897
[TBL] [Abstract][Full Text] [Related]
16. Assessment of asymptomatic microscopic hematuria in adults.
Sharp VJ; Barnes KT; Erickson BA
Am Fam Physician; 2013 Dec; 88(11):747-54. PubMed ID: 24364522
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria.
Sagnak L; Ersoy H; Gucuk O; Ozok U; Topaloglu H
Urol Int; 2011; 87(1):35-41. PubMed ID: 21654152
[TBL] [Abstract][Full Text] [Related]
18. NMP22 is a sensitive, cost-effective test in patients at risk for bladder cancer.
Zippe C; Pandrangi L; Agarwal A
J Urol; 1999 Jan; 161(1):62-5. PubMed ID: 10037369
[TBL] [Abstract][Full Text] [Related]
19. Comparative evaluation of the nuclear matrix protein, fibronectin, urinary bladder cancer antigen and voided urine cytology in the detection of bladder tumors.
Eissa S; Swellam M; Sadek M; Mourad MS; El Ahmady O; Khalifa A
J Urol; 2002 Aug; 168(2):465-9. PubMed ID: 12131289
[TBL] [Abstract][Full Text] [Related]
20. Neural network using combined urine nuclear matrix protein-22, monocyte chemoattractant protein-1 and urinary intercellular adhesion molecule-1 to detect bladder cancer.
Parekattil SJ; Fisher HA; Kogan BA
J Urol; 2003 Mar; 169(3):917-20. PubMed ID: 12576812
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]